全文获取类型
收费全文 | 102篇 |
免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 8篇 |
临床医学 | 14篇 |
内科学 | 34篇 |
神经病学 | 9篇 |
特种医学 | 3篇 |
外科学 | 11篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 4篇 |
肿瘤学 | 15篇 |
出版年
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 3篇 |
2017年 | 1篇 |
2016年 | 1篇 |
2014年 | 4篇 |
2013年 | 7篇 |
2012年 | 6篇 |
2011年 | 6篇 |
2010年 | 2篇 |
2009年 | 4篇 |
2008年 | 9篇 |
2007年 | 8篇 |
2006年 | 9篇 |
2005年 | 10篇 |
2004年 | 10篇 |
2003年 | 2篇 |
2002年 | 3篇 |
2001年 | 3篇 |
1999年 | 2篇 |
1995年 | 1篇 |
1990年 | 1篇 |
1988年 | 1篇 |
1984年 | 1篇 |
1873年 | 3篇 |
1871年 | 1篇 |
排序方式: 共有103条查询结果,搜索用时 0 毫秒
61.
Betrosian AP Balla M Papanikolaou M Christopoulou M Kitsios A Farmakis E Georgiadis G 《The American journal of the medical sciences》2004,327(6):373-375
Purpura fulminans (PF) is a life-threatening disorder characterized by acute onset of progressive cutaneous hemorrhage, necrosis, and disseminated intravascular coagulation. Acute infectious PF occurs most commonly in the setting of meningococcal sepsis. When PF occurs in the setting of systemic lupus erythematosus (SLE), the catastrophic antiphospholipid antibody syndrome (CAPS) must be ruled out because urgent therapy is required. Plasmapheresis is effective in both cases, but immunosuppression (high-dose corticosteroids plus cyclophosphamide), although beneficial in patients with CAPS, could be harmful in patients with meningococcal PF. The authors report here a patient with SLE who presented to the intensive care unit with meningococcal PF, acute renal failure, and acute respiratory distress syndrome and discuss clinical similarities and laboratory differences from CAPS. 相似文献
62.
63.
64.
65.
John Papanikolaou Demosthenes Makris Theodosios Saranteas Dimitrios Karakitsos Elias Zintzaras Andreas Karabinis Georgia Kostopanagiotou Epaminondas Zakynthinos 《Intensive care medicine》2011,37(12):1976-1985
Purpose
To investigate the diagnostic performance of Doppler echocardiography (DE) in predicting the outcome of weaning from mechanical ventilation in patients without overt cardiac disease. 相似文献66.
Maria C. Diakou Evangelos N. Liberopoulos Dimitri P. Mikhailidis Epaminondas V. Tsianos Andrew K. Burroughs 《Scandinavian journal of gastroenterology》2013,48(2):139-147
125I-protein-radioiodinated pure pancreatic juice samples from patients with adenocarcinoma of the pancreas, chronic pancreatitis, or intact pancreas were analysed by high-resolution SDS-polyacrylamide gel electrophoresis and subsequent autoradiography. Experiments resulted in the detection of a 180K protein, probably a glycoprotein, in the pure pancreatic juice from pancreatic carcinoma (93%) and chronic pancreatitis (73%) patients, which was completely absent from pancreatic juice from intact pancreas. Sephadex G-200-isolated 18UK protein was found to be different from carcinoembryonic antigen (CEA) when traced by a commercial CEA radioimmunoassay, but it seemed identical in pancreatic juice samples from patients with pancreatic carcinoma and chronic pancreatitis, at least with regard to isoelectric point. In brief, the present results suggest that 180K protein identification in pancreatic juice permits adenocarcinoma of the pancreas and chronic pancreatitis to be differentiated from normal conditions but that distinction between pancreatic carcinoma and chronic pancreatitis is unlikely. 相似文献
67.
Kiortsis DN Nikas S Hatzidimou K Tsianos E Elisaf MS 《Fundamental & clinical pharmacology》2003,17(4):491-494
The most important side effects of fibrate and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) treatment are hepatic toxicity and myopathy. Obese individuals may have higher levels of serum transaminases than their lean counterparts. The main purpose of this study was to examine the effects of statins and fibrates on liver enzymes in obese patients and to compare them with their effects on patients with various body mass indexes (BMI). Two hundred and sixty-three hyperlipidemic patients of both sexes aged 31-74 years were studied for 24 weeks. One hundred and three patients received fluvastatin (40 mg/day), 62 atorvastatin (10-20 mg/day), 45 micronized fenofibrate (200 mg/day), 44 ciprofibrate (100 mg/day) and nine patients received gemfibrozil (900 mg/day). Laboratory determinations were performed at baseline, after 8 weeks of treatment and at the end of the follow-up period. At baseline, obese patients tended to exhibit elevated liver enzymes more frequently than their lean counterparts (12 of 105 vs. 5 of 67). At the end of the study period, 11 obese, seven overweight and six lean subjects exhibited elevated liver enzymes. Twelve patients who experienced a moderate elevation of serum liver enzymes at baseline had their liver enzyme profile normalized at the end of the study. Furthermore, in 12 patients who had normal serum liver enzyme levels at baseline, abnormal levels of at least one enzyme were observed after 24 weeks of treatment. Fibrates and statins are safe drugs for the treatment of hyperlipidemia in obese patients as well as in those with moderately increased liver enzymes. 相似文献
68.
69.
Christodoulou C Kalofonos HP Briasoulis E Bafaloukos D Makatsoris T Koutras A Skarlos DV Samantas E 《Cancer chemotherapy and pharmacology》2006,57(2):207-212
Purpose: To assess the safety and efficacy of a 3-day schedule of cisplatin and topotecan in patients with recurrent small-cell lung
cancer (SCLC). Methods: Thirty-four relapsed patients were treated with cisplatin 20 mg/m2 and topotecan 0.9 mg/m2, both given on days 1–3 every 3 weeks, in a phase II study. Results: Complete response (CR) was achieved in two patients (6%), partial response (PR) in 4 (12%), stable disease in 6 (18%) and
progressive disease in 14 (41%). Eight patients (23%) were non-evaluable for response. Among 21 sensitive patients, 2 (9.5%)
achieved CR and 3 (14%) PR. Among 13 refractory patients, none achieved CR and only 1 (8%) PR. Median survival was 6.5 months
for all patients, 7.8 for sensitive and 6.2 for refractory. Median time to progression (TTP) was 4.4 months for all patients,
5.9 for sensitive and 3.2 for refractory. Grade 3–4 toxicities included anemia (15%), thrombocytopenia (15%), neutropenia
(42%), nausea/vomiting (3%), and alopecia (6%). No toxic death occurred. Conclusions: This 3-day schedule was well tolerated, produced modest response rates but good survival and TTP both in sensitive and refractory
patients with relapsed SCLC. 相似文献
70.
Pentheroudakis G Fountzilas G Bafaloukos D Koutsoukou V Pectasides D Skarlos D Samantas E Kalofonos HP Gogas H Pavlidis N 《Breast cancer research and treatment》2006,97(3):237-244
SummaryIntroduction Breast cancer patients developing liver metastases have traditionally been considered to make up a poor prognosis group with median survival rates of less than 6 months. We retrospectively analysed clinicopathologic characteristics of 500 women with metastatic breast cancer and liver deposits upon administration of first-line chemotherapy in the 90s. We sought to examine the epidemiology, clinical course, outcome and prognostic factors of this cohort with the hope to identify changing patterns, facilitate cost-effective follow-up and rationalize therapy of these patients.Materials and methods Among 1426 metastatic breast cancer patients enrolled with the Hellenic Cooperative Oncology Group (HeCOG) chemotherapy registry from 1988 to 2004, 500 (35%) had liver deposits when first-line chemotherapy was administered and were the subject of this retrospective analysis. These patients had been treated with single-agent or combination chemotherapy either in the context of clinical trials or outwith trials according to standard HeCOG protocols.Results Median age at diagnosis was 54.5 years, with the majority of women being fit (Performance Status PS 0–1 76%), postmenopausal (53%) harbouring hormone-receptor positive (54%) invasive ductal, lobular or mixed carcinomas (76%). High-grade tumours were present in 35% of patients, while the extent of systemic relapse was confined to the liver plus none or one additional organ site in 59% of women. Half of the patients had received adjuvant chemotherapy and two-thirds relapsed later than 12 months from initial diagnosis of localized disease. First-line palliative chemotherapy included an anthracycline and/or a taxane in 88% of cases with an objective response rate of 34% (95% Confidence Interval CI: 29.1–37.5), while 79% of patients were able to proceed to second-line chemotherapy based mostly on non-anthracycline non-taxane containing regimens with objective responses seen in 16% of them (95% CI: 11.6–21.9). At a median follow-up of 47.5 months, disease progression occurred solely in the liver in one-third of patients and median overall survival was 16.3 months, with projected 5-year survival of 8.5%. Type of palliative chemotherapy was not a predictive factor for response, though non-anthracycline non-taxane regimens were associated with lower tumour regression rates. Positive hormonal receptor status of the primary, low histological grade, malignant relapse in the liver only or liver plus one organ site and good performance status were significant prognostic factors for improved outcome in univariate analysis, the latter two retaining significance in multivariate analysis as well.Conclusions In comparison to historical series, adjuvant therapy, stricter follow up and imaging technology advances result in earlier diagnosis of fitter breast cancer patients with low-volume hepatic and systemic relapse. Cost-effectiveness of close monitoring for early diagnosis of relapse should be further studied. With availability of effective modern chemotherapy, prolonged survival is feasible and aggressive multidisciplinary management of selected patients may be warranted. 相似文献